＜Research＞Nomura Drops CSPC PHARMA (01093.HK) TP to $9.83, Expects 2Q Rev. Growth to Slow Down

　　Nomura issued a research note, lowering its profit forecasts for this year and next year by 1.4% each for CSPC PHARMA (01093.HK) -0.030 (-0.493%) Short selling $21.39M; Ratio 15.020% , reflecting a slight upward revision to its selling expenses forecast, and keeping its revenue forecast unchanged. The broker expected its revenue to slow down in 2Q24, but still rise 4.5% YoY to RMB8.39 billion, while earnings would drop 3% YoY.

　　Nomura trimmed its target price on CSPC PHARMA from $10.07 to $9.83 and maintained its Buy rating.

　　Related NewsCICC: Re-entry Into High Div. Theme Should Wait Until Sufficient Pullback; Prefers Semiconductors/ Autos/ Medias/ Softwares/ Biotechs in Short Term

　　(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-22 16:25.)

　　AAStocks Financial News